Skip to content
10-K

Annual Report

ZYVERSA THERAPEUTICS, INC. ZVSA

0001641172-25-000862

← back to feed
Filed
Mar 27, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 20, 2025 2.57M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 97.5K sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$8.72M
Current Liabilities FY 2024 · Dec 31, 2023 $10.19M
Total Liabilities FY 2024 · Dec 31, 2023 $11.04M
Current Assets FY 2024 · Dec 31, 2023 $3.35M
Total Assets FY 2024 · Dec 31, 2023 $22.11M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$1,089.70
Eps Basic restated FY 2024 · Dec 31, 2023 −$1,089.70
Sga Expense FY 2024 · Dec 31, 2023 $11.21M
Rd Expense FY 2024 · Dec 31, 2023 $3.21M
Net Income FY 2024 · Dec 31, 2023 −$98.3M
Operating Income FY 2024 · Dec 31, 2023 −$107.75M
Stockholders Equity FY 2024 · Dec 31, 2022 $99.66M